Firm reclassifies previous revenues from its now-divested license for Tysabri royalties, garnering tax benefits in earlier periods. Perrigo's review of its 2014-2016 results also uncovered $19m in 2016 net income for its European consumer products business.
Perrigo Co. PLC's restating of several years of financials drives home the point that its primary sales driver is consumer health care products while encouraging investors enough to maintain a recent share price increase after an extended slump.
The US private label OTC market leader restated earnings reports for its fiscal years 2014 and 2015 and filed with...
Developments in India and Pakistan are designed to standardize how drug companies disclose their expenses associated with health care professionals.
AbbVie’s migraine ad overstates the drug’s benefit, a problem that is amplified by using a celebrity, the agency says.
The lung cancer drug Krazati from Bristol Myers Squibb’s Mirati Therapeutics drew an FDA ad/promo untitled letter, highlighting the agency's trend of pursuing false or misleading efficacy claims, particularly when data comes from outside approved labeling.
The UK and EU pharma industry associations have defended their respective codes of practice despite alarming study results. Meanwhile, a consultation on proposals to revise the UK code received over 3,500 comments.
Joint clinical assessment reports must be descriptive rather than reach definitive conclusions, and must not interfere with national decision making processes, according to new EU guidance.
Developments in India and Pakistan are designed to standardize how drug companies disclose their expenses associated with health care professionals.
The agency’s plan for advanced manufacturing seeks more harmonization, while also seeking to codify internal practices with guidance and training.
